Lion Dumps Discovery Unit, Fine-Tunes Strategy to Penetrate Top-Tier Pharma | GenomeWeb

The business model shuffle continues in the bioinformatics sector, with the latest move coming from Lion Bioscience.

After fruitlessly shopping its iD3 drug-discovery business around to potential buyers for three months, the company has bitten the bullet and dissolved the unit completely, vowing to become a market success on the strength of its life science IT solutions alone.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.